Ciprofloxacin versus vancomycin in the therapy of experimental methicillin-resistant Staphylococcus aureus endocarditis.
about
Ciprofloxacin therapy of experimental endocarditis caused by methicillin-resistant Staphylococcus epidermidisCiprofloxacin therapy of experimental endocarditis caused by methicillin-susceptible or methicillin-resistant Staphylococcus aureusEfficacy of pefloxacin-fosfomycin in experimental endocarditis caused by methicillin-resistant Staphylococcus aureusLysostaphin treatment of experimental methicillin-resistant Staphylococcus aureus aortic valve endocarditis.Evaluation of quinolones in experimental animal models of infections.Efficacy of trovafloxacin against experimental Staphylococcus aureus endocarditis.Efficacy of LY333328 against experimental methicillin-resistant Staphylococcus aureus endocarditisBactericidal activities of teicoplanin, vancomycin, and gentamicin alone and in combination against Staphylococcus aureus in an in vitro pharmacodynamic model of endocarditis.Comparison of a rabbit model of bacterial endocarditis and an in vitro infection model with simulated endocardial vegetations.In vitro and in vivo activities of a novel cephalosporin, BMS-247243, against methicillin-resistant and -susceptible staphylococciComparative efficacies of human simulated exposures of telavancin and vancomycin against methicillin-resistant Staphylococcus aureus with a range of vancomycin MICs in a murine pneumonia model.CI-960, a new fluoroquinolone, for therapy of experimental ciprofloxacin-susceptible and -resistant Staphylococcus aureus endocarditis.Ciprofloxacin-resistant methicillin-resistant Staphylococcus aureus in an acute-care hospital.Daptomycin compared with teicoplanin and vancomycin for therapy of experimental Staphylococcus aureus endocarditis.Development of resistance to fleroxacin during therapy of experimental methicillin-susceptible Staphylococcus aureus endocarditisFluoroquinolones. New miracle drugs?Vancomycin or vancomycin plus netilmicin for methicillin- and gentamicin-resistant Staphylococcus aureus aortic valve experimental endocarditisEfficacy of fleroxacin in experimental methicillin-resistant Staphylococcus aureus endocarditis.Ciprofloxacin and rifampin, alone and in combination, for therapy of experimental Staphylococcus aureus endocarditisQuinolone resistance in Pseudomonas aeruginosa and Staphylococcus aureus. Development during therapy and clinical significance.Effect of teicoplanin on Staphylococcus aureus with heterointermediate susceptibility to glycopeptides in experimental infective endocarditis model.Evaluation of daptomycin treatment of Staphylococcus aureus bacterial endocarditis: an in vitro and in vivo simulation using historical and current dosing strategies.
P2860
Q28334677-89D32D28-A69C-45FC-A873-F1B616919788Q28361123-680D7F0B-240B-4F83-B87F-114BCD237498Q28361126-B6C77444-7D00-419C-B335-3FEC11937570Q28379547-20D60509-9130-4F6C-8A9F-E094652398BFQ30446615-F5B6C89C-35D0-4125-8082-9BEB1DB9D8B2Q33689451-41364F13-506B-477B-AE93-BDC16315CB39Q33693084-A2F7119C-CE8B-4D52-AD2C-4DD846649F30Q33758399-63AD4A69-89B4-453F-A0E2-0E047C4A66E5Q33980069-A3EB2663-2661-4A38-9960-CF603F7A152BQ34105659-ACF555B4-8AF1-40F5-9E44-1B244F328AE1Q34309620-F06765B6-F7C1-4C8C-B30C-C53A9B75A2D4Q34537953-EF9F15E1-0CCB-4E0D-835A-7E42A18ABC3DQ35279768-1BF83891-1B81-4D91-963E-7963DADD79A5Q35280233-A32C20EB-8848-4568-9AB3-B2EE289BA844Q36754440-6A427DC7-C554-4427-B59F-2ADD1DACE725Q37620490-3D4DF458-2D24-46C1-8902-03B86DD96546Q39780630-EB3E152B-B088-4BE9-9981-79E4F87725ADQ39819019-9F8A7CB6-9A9C-4754-ACD9-B68C7B450812Q39819605-D9B8592D-7B48-4A3F-9F0D-7B351D96230DQ40633555-6BDF5159-D607-47B3-9C8C-B5C72FFB298EQ41229114-A7366BB3-6BC9-439A-BEC5-E8107179CB8DQ50991026-7A46EBCC-7294-401E-90F1-0B2FAF081C2C
P2860
Ciprofloxacin versus vancomycin in the therapy of experimental methicillin-resistant Staphylococcus aureus endocarditis.
description
1987 nî lūn-bûn
@nan
1987年の論文
@ja
1987年学术文章
@wuu
1987年学术文章
@zh-cn
1987年学术文章
@zh-hans
1987年学术文章
@zh-my
1987年学术文章
@zh-sg
1987年學術文章
@yue
1987年學術文章
@zh
1987年學術文章
@zh-hant
name
Ciprofloxacin versus vancomyci ...... ylococcus aureus endocarditis.
@en
Ciprofloxacin versus vancomyci ...... ylococcus aureus endocarditis.
@nl
type
label
Ciprofloxacin versus vancomyci ...... ylococcus aureus endocarditis.
@en
Ciprofloxacin versus vancomyci ...... ylococcus aureus endocarditis.
@nl
prefLabel
Ciprofloxacin versus vancomyci ...... ylococcus aureus endocarditis.
@en
Ciprofloxacin versus vancomyci ...... ylococcus aureus endocarditis.
@nl
P2093
P2860
P356
P1476
Ciprofloxacin versus vancomyci ...... ylococcus aureus endocarditis.
@en
P2093
P2860
P304
P356
10.1128/AAC.31.4.527
P407
P577
1987-04-01T00:00:00Z